Les lignes directrices cliniques comme un travail en cours continu : avancer à la vitesse de la science

“The findings demonstrate that lower, more aggressive lowering of LDL-C with use of evolocumab improves outcomes in a high-risk primary prevention population and likely endorses early clinical adoption of lower LDL-C thresholds in patients like those in the VESALIUS-CV cohort.”